NO20082880L - Inhibitorer av C-MET samt anvendelse derav - Google Patents

Inhibitorer av C-MET samt anvendelse derav

Info

Publication number
NO20082880L
NO20082880L NO20082880A NO20082880A NO20082880L NO 20082880 L NO20082880 L NO 20082880L NO 20082880 A NO20082880 A NO 20082880A NO 20082880 A NO20082880 A NO 20082880A NO 20082880 L NO20082880 L NO 20082880L
Authority
NO
Norway
Prior art keywords
inhibitors
met
provides
compounds
utilizing
Prior art date
Application number
NO20082880A
Other languages
English (en)
Inventor
Jon Come
Alexander Aronov
David Lauffer
Pan Li
David DEININGER
Kira Mcginty
Dean Stamos
Michelle Stewart
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20082880L publication Critical patent/NO20082880L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Den foreliggende oppfinnelsen fremskaffer forbindelser som er nyttige som hemmere av c-Met tyrosinkinase. Oppfinnelsen fremskaffer også farmasøytisk akseptable blandinger som inneholder oppfinnelsens forbindelser og metoder til å benytte blandingene til behandling av forskjellige proliferative forstyrrelser.
NO20082880A 2005-11-30 2008-06-30 Inhibitorer av C-MET samt anvendelse derav NO20082880L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74074105P 2005-11-30 2005-11-30
US74085905P 2005-11-30 2005-11-30
US74073705P 2005-11-30 2005-11-30
PCT/US2006/045847 WO2007064797A2 (en) 2005-11-30 2006-11-30 Inhibitors of c-met and uses thereof

Publications (1)

Publication Number Publication Date
NO20082880L true NO20082880L (no) 2008-09-01

Family

ID=37998312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082880A NO20082880L (no) 2005-11-30 2008-06-30 Inhibitorer av C-MET samt anvendelse derav

Country Status (12)

Country Link
US (2) US7728017B2 (no)
EP (1) EP1963329B1 (no)
JP (1) JP5144532B2 (no)
KR (1) KR20080080584A (no)
AU (1) AU2006320580B2 (no)
BR (1) BRPI0619252A2 (no)
CA (1) CA2630884A1 (no)
IL (1) IL191623A0 (no)
MX (1) MX2008007049A (no)
NO (1) NO20082880L (no)
NZ (1) NZ568666A (no)
WO (1) WO2007064797A2 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO340958B1 (no) * 2005-12-21 2017-07-31 Janssen Pharmaceutica Nv Triazolopyridaziner som tyrosinkinase modulatorer

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591784B1 (en) 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
WO2007138472A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
DK2044026T3 (da) 2006-06-22 2014-06-30 Prana Biotechnology Ltd Fremgangsmde til behandling af cerebral glioma tumor
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
WO2008011045A2 (en) * 2006-07-18 2008-01-24 Cytovia, Inc. 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
CN101796056A (zh) 2006-09-18 2010-08-04 沃泰克斯药物股份有限公司 c-MET的杂环抑制剂及其用途
NO346024B1 (no) 2006-11-22 2022-01-03 Incyte Holdings Corp Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
PT2193133E (pt) 2007-09-27 2015-10-22 Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazóis para utilização como inibidores de proteína quinases
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
RU2011124894A (ru) * 2008-11-19 2012-12-27 Вертекс Фармасьютикалз Инкорпорейтед Триазолотиадиазоловый ингибитор протеинкиназы с-мет
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
KR101663335B1 (ko) 2008-12-22 2016-10-06 메르크 파텐트 게엠베하 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
KR20110113755A (ko) 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
EP2406264A4 (en) 2009-03-09 2012-08-08 Univ California SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINE AND GABAA RECEPTORS
EA022753B1 (ru) 2009-04-02 2016-02-29 Фундасьон Сентро Насиональ Де Инвестигасьонес Онколохикас Карлос Iii Имидазотиадиазолы для применения в качестве ингибиторов киназ
EP2435445A1 (en) * 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of c-met protein kinase
EP2435444A1 (en) 2009-05-28 2012-04-04 Vertex Pharmaceuticals Incorporated Substituted pyrazole inhibitors of c-met protein kinase
JP5686796B2 (ja) * 2009-05-28 2015-03-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
ME02211B (me) 2009-12-31 2016-02-20 Hutchison Medipharma Ltd Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
EP2576568A1 (en) * 2010-05-27 2013-04-10 Vertex Pharmaceuticals Incorporated An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
WO2012158658A1 (en) 2011-05-16 2012-11-22 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
PE20161219A1 (es) 2011-11-11 2016-11-17 Pfizer 2-tiopirimidinonas
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
MX359888B (es) 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
KR20160048988A (ko) 2013-09-06 2016-05-04 인셉션 2 인코퍼레이티드 트라이아졸론 화합물 및 이의 용도
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
BR112016006444B1 (pt) 2013-09-30 2021-01-19 Korea Research Institute Of Chemical Technology derivado de triazolopirazina e composições farmacêuticas compreendendo o mesmo
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3285764B1 (en) * 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
CA2990791A1 (en) * 2015-06-25 2016-12-29 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
KR101742782B1 (ko) 2015-07-02 2017-06-01 공주대학교 산학협력단 신규의 트리아졸로티아디아졸 화합물, 이의 용도, 및 이를 포함한 유기발광소자
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP6936796B2 (ja) 2015-07-06 2021-09-22 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼのヘテロハロ阻害剤
EP3362442B1 (en) 2015-10-14 2020-01-29 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
UY37026A (es) 2015-12-16 2017-06-30 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
CA3018346A1 (en) 2016-03-24 2017-09-28 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
GR1009565B (el) * 2016-07-14 2019-08-06 Galenica Α.Ε. Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
MA47516A (fr) 2017-02-15 2021-03-31 Taiho Pharmaceutical Co Ltd Composition pharmaceutique
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
JP7234201B2 (ja) * 2017-07-12 2023-03-07 ブリストル－マイヤーズ スクイブ カンパニー 心不全の治療のためのｒｏｃｋの５員アミノヘテロ環および５，６－または６，６員二環式アミノヘテロ環の阻害剤
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
TR202009388A1 (tr) * 2020-06-17 2021-12-21 Anadolu Ueniversitesi Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
TR202010296A1 (tr) 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
CN117355523A (zh) * 2021-03-17 2024-01-05 武田药品工业株式会社 血浆激肽释放酶的多环抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
AP3433A (en) 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO340958B1 (no) * 2005-12-21 2017-07-31 Janssen Pharmaceutica Nv Triazolopyridaziner som tyrosinkinase modulatorer

Also Published As

Publication number Publication date
IL191623A0 (en) 2008-12-29
AU2006320580B2 (en) 2011-06-23
NZ568666A (en) 2011-09-30
US7728017B2 (en) 2010-06-01
EP1963329B1 (en) 2013-01-23
WO2007064797A3 (en) 2007-12-13
CA2630884A1 (en) 2007-06-07
BRPI0619252A2 (pt) 2011-09-20
US20070191369A1 (en) 2007-08-16
JP2009518296A (ja) 2009-05-07
US7998987B2 (en) 2011-08-16
EP1963329A2 (en) 2008-09-03
AU2006320580A1 (en) 2007-06-07
JP5144532B2 (ja) 2013-02-13
KR20080080584A (ko) 2008-09-04
US20100190774A1 (en) 2010-07-29
MX2008007049A (es) 2008-10-23
WO2007064797A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
NO20084435L (no) C-MET proteinkinaseinhibitorer
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
ATE554087T1 (de) Neue kinaseinhibitoren
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
TW200801008A (en) Protein kinase inhibitors
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20082746L (no) Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application